摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-1-benzyl-2-methylpyrrolidine | 862307-40-2

中文名称
——
中文别名
——
英文名称
(R)-1-benzyl-2-methylpyrrolidine
英文别名
(2R)-1-benzyl-2-methylpyrrolidine
(R)-1-benzyl-2-methylpyrrolidine化学式
CAS
862307-40-2
化学式
C12H17N
mdl
——
分子量
175.274
InChiKey
PABZWDUKSBQYMP-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    3.2
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
    —— N-benzylpent-4-en-1-amine 54436-58-7 C12H17N 175.274

反应信息

  • 作为产物:
    描述:
    N-benzylpent-4-en-1-amine 在 C67H78IrN2(1+)*F6P(1-) 作用下, 以20%的产率得到
    参考文献:
    名称:
    用于多种未活化氨基烯烃分子内氢胺化的高活性和选择性手性 NHC-铱催化剂的设计、范围和机理
    摘要:
    引入手性阳离子 NHC-铱配合物作为未活化氨基烯烃分子内氢胺化反应的催化剂。该催化剂在构建一系列 5 元和 6 元 N 杂环时表现出高活性,这些杂环具有优异的光学纯度,并且该系统可以耐受各种官能团。通过使用替代反应条件呈现和消除主要的失活途径。对反应机理进行了详细的实验和计算研究,为催化系统的作用模式提供了有价值的见解,并指出了对该催化平台的未来修改。
    DOI:
    10.1039/d0sc05884j
点击查看最新优质反应信息

文献信息

  • [EN] PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS PHÉNOXY-PYRIDYL-PYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
    申请人:GENENTECH INC
    公开号:WO2020056089A1
    公开(公告)日:2020-03-19
    Described herein are phenoxy-pyridyl -pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    本文描述了具有肌醇需要酶1(IRE1)调节活性或功能的吡啶嘧啶化合物,其具有Formula I结构或立体异构体、互变异构体或其药用可接受的盐,并具有所述的取代基和结构特征。还描述了包括Formula I化合物的药物组合物和药物,以及使用这种IRE1调节剂的方法,单独或与其他治疗剂联合使用,用于治疗通过雌激素受体介导或依赖的疾病或症状。
  • Processes for Producing Optically Active 1-Substituted 2-Methylpyrrolidine and Intermediate Therefor
    申请人:Nishiyama Akira
    公开号:US20070292926A1
    公开(公告)日:2007-12-20
    The present invention relates to a process for producing an optically active 1,4-pentanediol by asymmetrically reducing 5-hydroxy-2-pentanone, which is easily available at low cost. The present invention also relates to a process for producing an optically active 1-substituted 2-methylpyrrolidine including sulfonylating the optically active 1,4-pentanediol to convert it to an optically active sulfonate compound, and reacting the compound with an amine. According to the processes of the present invention, an optically active 1,4-pentanediol and an optically active 1-substituted 2-methylpyrrolidine, which are useful as an intermediate for medicines and an intermediate for agricultural chemicals, can be simply produced from an inexpensive starting material.
    本发明涉及一种生产光学活性1,4-戊二醇的过程,该过程通过非对称还原低成本易得的5-羟基-2-戊酮。本发明还涉及一种生产光学活性1-取代-2-甲基吡咯烷的过程,包括将光学活性1,4-戊二醇磺酰化以转化为光学活性磺酸盐化合物,并将该化合物与胺反应。根据本发明的工艺,可以从廉价的起始材料简单地生产出作为药物中间体和农药中间体的光学活性1,4-戊二醇和光学活性1-取代-2-甲基吡咯烷
  • N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
    申请人:John Varghese
    公开号:US20070213316A1
    公开(公告)日:2007-09-13
    Disclosed are compounds of the formula wherein the variables R N , R C , R 1 , R 25 , R 2 , and R 3 are as defined herein. These compounds have activity as inhibitors of beta-secretase and are therefore useful in treating a variety of discorders such as Alzheimer's Disease.
    本发明揭示了以下式子的化合物:其中变量RN,RC,R1,R25,R2和R3如本文所定义。这些化合物具有抑制β-分泌酶的活性,因此可用于治疗多种疾病,例如阿尔茨海默病。
  • Benzimidazole derivatives and their use as protein kinases inhibitors
    申请人:Berdini Valerio
    公开号:US20070135477A1
    公开(公告)日:2007-06-14
    The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.
    该发明提供了式(1)的化合物: 这些化合物具有对环素依赖性激酶、糖原合成酶激酶和Auroa激酶的活性,因此可用于治疗癌症和病毒性疾病。
  • Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
    申请人:Berdini Valerio
    公开号:US20080312223A1
    公开(公告)日:2008-12-18
    The invention provides a compound of the formula (I): or a salt, N-oxide, tautomer or solvate thereof, wherein X is CR 5 or N; each of Q 1 and Q 2 is a carbon atom; Q 3 is selected from S and CH; Q 4 is selected from CR 2 and S; provided that one of Q 3 and Q 4 is S and the other of Q 3 and Q 4 is not S; wherein when Q 3 is S, there is a double bond between Q 1 and Q 4 and a double bond between Q 2 and the adjacent ring nitrogen atom N; and when Q 4 is S, there is a double bond between Q 1 and Q 2 , and a double bond between Q 3 and the adjacent ring nitrogen atom N; A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR 8 (C═O) or O(C═O) wherein R 1 is hydrogen or C1_4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R o is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; R 1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C 1-8 hydrocarbyl group; R 2 is hydrogen, halogen, methoxy, or a C 1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy; R 3 and R 4 together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and R 5 is hydrogen, a group R 2 or a group R 10 wherein R 10 is as defined in the claims. The compounds have activity as inhibitors of cyclin dependent kinases, glycogen synthase kinases and Aurora kinases.
    本发明提供一种化合物,其化学式为(I)或其盐,N-化物,互变异构体或溶剂化物,其中X为CR5或N; Q1和Q2中的每一个都是原子; Q3从S和CH中选择; Q4从CR2和S中选择; 假设Q3和Q4中的一个是S,而另一个不是S; 当Q3为S时,Q1和Q4之间有一个双键,Q2和相邻的环原子N之间有一个双键; 当Q4为S时,Q1和Q2之间有一个双键,并且Q3和相邻的环原子N之间有一个双键; A是键或-(CH2)m-(B)n-; B为C═O,NR8(C═O)或O(C═O),其中R1为或C1_4烃基,可选择地被羟基或C1-4烷基取代; m为0、1或2; n为0或1; Ro为或与NRg一起形成一个群体-( )p-,其中p为2至4; R1为,具有3至12个环成员的环或杂环基,或可选择地被取代的C1-8烃基基团; R2为、卤素、甲基或可选择地被卤素、羟基或甲基取代的C1-4烃基基团; R3和R4与它们所连接的原子一起形成一个可选择地取代的融合环或杂环环,其具有5至7个环成员,其中最多可有3个异原子,选择自N、O和S; R5为、R2基团或R10基团,其中R10如权利要求所定义。该化合物具有作为细胞周期依赖性激酶、糖原合成酶激酶和极化子激酶的抑制剂的活性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫

可以介绍下你们的产品么

你们是怎么收费的呢

可以开发票吗?